EMEA - THERASPHERETM Y-90 MASTERCLASS 
Evolving Liver Cancer Patient Care

October 26-27 2026
Dusseldorf, Germany

EMEA - THERASPHERETM Y-90 MASTERCLASS
Evolving Liver Cancer Patient Care

Learning journey

Target Audience
Experienced TheraSphere™ users interested in elevating their treatment strategies in liver cancers, including and beyond HCC, strengthening their MDT discussions and advancing their personalised dosimetry techniques.

Course Overview
Experienced TheraSphere™ users interested in elevating their treatment strategies in liver cancers, including and beyond HCC, strengthening their MDT discussions and advancing their personalised dosimetry techniques.

  • Provide a thorough understanding of TheraSphere™ Therapy from patient selection to post-treatment care
  • Discuss treatment strategies for liver cancer patient, integrating cost-effectiveness data into treatment decision-making.
  • Increasing participants' confidence in attending MDT meetings advocating for TheraSphere™
  • Explore the integration of TheraSphere™ with other treatment modalities to enhance patient outcome.

Faculty

Prof. Irene Bargellini: Interventional Radiologist, Universita degli Studi di Torino

Prof. Leonie Jochheim: Gastroenterology and Hepatology, University Hospital Essen

Dr. Iñigo Insausti: Interventional Radiologist, Hospital Universitario de Navarra - Pamplona

Prof. Arhtur Braat: Nuclear Medicine, UMC Utrecht

Dr. Peter Littler: Interventional Radiologist, Newcastle Hospital

Agenda day1

October 26-27, 2026

TimeSession / Topic
18:00-22:00Reception & Dinner

Agenda day2

October 26-27, 2026

TimeSession / Topic
9:00-9:10Opening Remarks & Scientific Objectives
9:10-9:40Two Decades of TheraSphere™: Evolution of Clinical Evidence and Patient Outcomes
9:40-10:10Evolution of Dosimetry in Y-90 Therapy
10:10-10:40Y-90 vs. TACE: Clinical Evidence and Tumor Board Decision-Making
10:40-11:00Coffee Break
11:00-11:30Combination Strategies: Y-90 and Immunotherapy in practice
11:30-12:00Managing PVT in HCC: Overcoming Treatment Gaps with Y-90
12:00-12:30Downstaging to curative HCC
12:30-13:30Lunch
13:30-15:00Breakout session:
• Case discussion Y-90 in non-HCC
• Case discussion How to optimize Y-90 dose distribution
15:00-15:30Integration of cost-effectiveness data into treatment decision making
15:30-16:00Expert Roundtable: Navigating Tumor Board Dynamics for Y-90 Success
16:00Closing Remarks & Departure

*Agenda timing and order may vary. The course is limited to 4 attendees per session and it will be customized to learners’ specific needs identified in advance of attendance.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. EP-1446803-AB © 2023 Boston Scientific Corporation or its affiliates. All rights reserved.